首页 > 最新文献

Current Opinion in Supportive and Palliative Care最新文献

英文 中文
Patient and carer experiences of cancer cachexia and its management. 癌症恶病质患者和护理者的经历及其管理。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1097/SPC.0000000000000710
Megan Bowers, Irene J Higginson, Matthew Maddocks

Purpose of review: To explore the contributions of recent qualitative literature in progressing understanding of the experiences of cancer cachexia, and its management, from the perspectives of patients and unpaid/family carers.

Recent findings: Challenges with conducting everyday activities, maintaining independence, and continuing usual roles within the family are sources of distress. Patients and carers value individualization, flexibility, and carer involvement in physical activity/exercise interventions. In psychosocial/educational interventions that were positively perceived, the opportunity to talk about cachexia was appreciated, leading to improved health literacy, awareness about nutrition, and relationships with food. However, the general patient and carer experience around clinical acknowledgement and management of cachexia remains poor.

Summary: Eating-related distress and conflicts, lack of understanding about cachexia, and the visibility of weight loss remain recurring themes amongst literature on experiences of cancer cachexia. Studies exploring preferences for, and experiences of, interventions have primarily focused on physical activity or exercise. Psychosocial/educational and physical activity/exercise interventions are valued and perceived to alleviate some of the key quality of life issues amongst patients with cancer cachexia and their unpaid/family carers.

综述的目的:从患者和无偿/家庭照护者的角度,探讨近期定性文献在加深理解癌症恶病质及其管理方面的贡献:进行日常活动、保持独立和继续扮演家庭中的常规角色所面临的挑战是痛苦的根源。患者和照护者重视个性化、灵活性以及照护者参与体育活动/锻炼干预。在得到积极评价的心理社会/教育干预措施中,谈论恶病质的机会得到了赞赏,从而提高了健康素养、对营养的认识以及与食物的关系。总结:与饮食相关的困扰和冲突、对恶病质缺乏了解以及体重减轻的可见性仍然是有关癌症恶病质体验的文献中反复出现的主题。探讨干预措施的偏好和经验的研究主要集中在体育活动或锻炼方面。社会心理/教育和体育活动/锻炼干预措施受到癌症恶病质患者及其无报酬/家庭照顾者的重视,并被认为能够缓解他们生活质量方面的一些关键问题。
{"title":"Patient and carer experiences of cancer cachexia and its management.","authors":"Megan Bowers, Irene J Higginson, Matthew Maddocks","doi":"10.1097/SPC.0000000000000710","DOIUrl":"10.1097/SPC.0000000000000710","url":null,"abstract":"<p><strong>Purpose of review: </strong>To explore the contributions of recent qualitative literature in progressing understanding of the experiences of cancer cachexia, and its management, from the perspectives of patients and unpaid/family carers.</p><p><strong>Recent findings: </strong>Challenges with conducting everyday activities, maintaining independence, and continuing usual roles within the family are sources of distress. Patients and carers value individualization, flexibility, and carer involvement in physical activity/exercise interventions. In psychosocial/educational interventions that were positively perceived, the opportunity to talk about cachexia was appreciated, leading to improved health literacy, awareness about nutrition, and relationships with food. However, the general patient and carer experience around clinical acknowledgement and management of cachexia remains poor.</p><p><strong>Summary: </strong>Eating-related distress and conflicts, lack of understanding about cachexia, and the visibility of weight loss remain recurring themes amongst literature on experiences of cancer cachexia. Studies exploring preferences for, and experiences of, interventions have primarily focused on physical activity or exercise. Psychosocial/educational and physical activity/exercise interventions are valued and perceived to alleviate some of the key quality of life issues amongst patients with cancer cachexia and their unpaid/family carers.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A traffic light approach for treatment and supportive care stratification in lung cancer. 肺癌治疗和支持护理分层的交通灯方法。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/SPC.0000000000000716
Iain Phillips, Lise Nottelmann, Mark Stares

Purpose of review: Comprehensive supportive care interventions for patients with lung cancer are being investigated in a range of ways, including: early palliative care, prehabilitation and rehabilitation. We review recent literature on supportive care and propose a traffic light system to individualise comprehensive supportive care. Green for those very likely to receive anti-cancer treatment, red for those very unlikely to receive anti-cancer treatment and orange where the chance of accessing treatment is uncertain. Comprehensive supportive care can be individualised based on the group a particular patient is in.

Recent findings: Lung cancer outcomes are improving with the availability of increasingly efficacious treatments; however, treatment rates for advanced disease remain low. In this review, we discuss how person-centred outcomes could be improved, how outcomes can be prognosticated and how the 'host' can be staged as well as the cancer. Recent data suggests that early comprehensive supportive care improves quality of life, reduces time spent in hospital and may affect survival.

Summary: Comprehensive supportive care is likely to improve quality of life in patients with advanced lung cancer. Further work is needed to see if it can improve treatment rates and survival.

综述目的:目前正在对肺癌患者的综合支持护理干预进行一系列研究,包括早期姑息治疗、预康复和康复。我们回顾了近期有关支持性护理的文献,并提出了一个交通灯系统,以实现综合支持性护理的个体化。绿色代表极有可能接受抗癌治疗,红色代表极不可能接受抗癌治疗,橙色代表接受治疗的可能性不确定。综合支持性护理可根据特定患者所处的组别进行个体化:随着疗效越来越好的治疗方法的出现,肺癌的治疗效果也在不断改善;然而,晚期疾病的治疗率仍然很低。在这篇综述中,我们讨论了如何改善以人为本的治疗效果、如何预测治疗效果以及如何对 "宿主 "和癌症进行分期。最近的数据表明,早期综合支持治疗可改善生活质量,减少住院时间,并可能影响生存期。摘要:综合支持治疗可能会改善晚期肺癌患者的生活质量。是否能提高治疗率和生存率还需要进一步研究。
{"title":"A traffic light approach for treatment and supportive care stratification in lung cancer.","authors":"Iain Phillips, Lise Nottelmann, Mark Stares","doi":"10.1097/SPC.0000000000000716","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000716","url":null,"abstract":"<p><strong>Purpose of review: </strong>Comprehensive supportive care interventions for patients with lung cancer are being investigated in a range of ways, including: early palliative care, prehabilitation and rehabilitation. We review recent literature on supportive care and propose a traffic light system to individualise comprehensive supportive care. Green for those very likely to receive anti-cancer treatment, red for those very unlikely to receive anti-cancer treatment and orange where the chance of accessing treatment is uncertain. Comprehensive supportive care can be individualised based on the group a particular patient is in.</p><p><strong>Recent findings: </strong>Lung cancer outcomes are improving with the availability of increasingly efficacious treatments; however, treatment rates for advanced disease remain low. In this review, we discuss how person-centred outcomes could be improved, how outcomes can be prognosticated and how the 'host' can be staged as well as the cancer. Recent data suggests that early comprehensive supportive care improves quality of life, reduces time spent in hospital and may affect survival.</p><p><strong>Summary: </strong>Comprehensive supportive care is likely to improve quality of life in patients with advanced lung cancer. Further work is needed to see if it can improve treatment rates and survival.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EDA2R-NIK signaling in cancer cachexia. 癌症恶病质中的 EDA2R-NIK 信号转导
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1097/SPC.0000000000000705
Samet Agca, Serkan Kir

Purpose of review: Cachexia is a debilitating condition causing weight loss and skeletal muscle wasting that negatively influences treatment and survival of cancer patients. The objective of this review is to describe recent discoveries on the role of a novel signaling pathway involving ectodysplasin A2 receptor (EDA2R) and nuclear factor κB (NFκB)-inducing kinase (NIK) in muscle atrophy.

Recent findings: Studies identified tumor-induced upregulation of EDA2R expression in muscle tissues in pre-clinical cachexia models and patients with various cancers. Activation of EDA2R by its ligand promoted atrophy in cultured myotubes and muscle tissue, which depended on NIK activity. The non-canonical NFκB pathway via NIK also stimulated muscle atrophy. Mice lacking EDA2R or NIK were protected from muscle loss due to tumors. Tumor-induced cytokine oncostatin M (OSM) upregulated EDA2R expression in muscles whereas OSM receptor-deficient mice were resistant to muscle wasting.

Summary: Recent discoveries revealed a mechanism involving EDA2R-NIK signaling and OSM that drives cancer-associated muscle loss, opening up new directions for designing anti-cachexia treatments. The therapeutic potential of targeting this mechanism to prevent muscle loss should be further investigated. Future research should also explore broader implications of the EDA2R-NIK pathway in other muscle wasting diseases and overall muscle health.

审查目的:恶病质是一种导致体重减轻和骨骼肌萎缩的衰弱病症,对癌症患者的治疗和生存产生负面影响。本综述旨在描述最近发现的涉及外胚层蛋白 A2 受体(EDA2R)和核因子κB(NFκB)诱导激酶(NIK)的新型信号通路在肌肉萎缩中的作用:研究发现,在临床前恶病质模型和各种癌症患者的肌肉组织中,肿瘤诱导 EDA2R 表达上调。EDA2R的配体激活促进了培养肌管和肌肉组织的萎缩,而这取决于NIK的活性。通过 NIK 的非经典 NFκB 通路也会刺激肌肉萎缩。缺乏 EDA2R 或 NIK 的小鼠不会因肿瘤而导致肌肉萎缩。肿瘤诱导的细胞因子oncostatin M(OSM)会上调肌肉中EDA2R的表达,而OSM受体缺乏的小鼠对肌肉萎缩有抵抗力:最近的发现揭示了一种涉及EDA2R-NIK信号转导和OSM的机制,该机制驱动癌症相关性肌肉萎缩,为设计抗痛风治疗方法开辟了新方向。针对这一机制预防肌肉萎缩的治疗潜力有待进一步研究。未来的研究还应探索 EDA2R-NIK 通路对其他肌肉萎缩疾病和整体肌肉健康的广泛影响。
{"title":"EDA2R-NIK signaling in cancer cachexia.","authors":"Samet Agca, Serkan Kir","doi":"10.1097/SPC.0000000000000705","DOIUrl":"10.1097/SPC.0000000000000705","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cachexia is a debilitating condition causing weight loss and skeletal muscle wasting that negatively influences treatment and survival of cancer patients. The objective of this review is to describe recent discoveries on the role of a novel signaling pathway involving ectodysplasin A2 receptor (EDA2R) and nuclear factor κB (NFκB)-inducing kinase (NIK) in muscle atrophy.</p><p><strong>Recent findings: </strong>Studies identified tumor-induced upregulation of EDA2R expression in muscle tissues in pre-clinical cachexia models and patients with various cancers. Activation of EDA2R by its ligand promoted atrophy in cultured myotubes and muscle tissue, which depended on NIK activity. The non-canonical NFκB pathway via NIK also stimulated muscle atrophy. Mice lacking EDA2R or NIK were protected from muscle loss due to tumors. Tumor-induced cytokine oncostatin M (OSM) upregulated EDA2R expression in muscles whereas OSM receptor-deficient mice were resistant to muscle wasting.</p><p><strong>Summary: </strong>Recent discoveries revealed a mechanism involving EDA2R-NIK signaling and OSM that drives cancer-associated muscle loss, opening up new directions for designing anti-cachexia treatments. The therapeutic potential of targeting this mechanism to prevent muscle loss should be further investigated. Future research should also explore broader implications of the EDA2R-NIK pathway in other muscle wasting diseases and overall muscle health.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validity of dietary intake methods in cancer cachexia. 癌症恶病质中膳食摄入方法的有效性。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1097/SPC.0000000000000709
Trude R Balstad, Marianne Bråtveit, Tora S Solheim, Lisa Heide Koteng, Asta Bye, Rasmus Dahl Jakobsen, Bente Schødt-Osmo, Siv Hilde Fjeldstad, Marianne Erichsen, Ola Magne Vagnildhaug, Ingvild Paur, Inger Ottestad

Purpose of review: Accurate assessment of dietary intake, especially energy and protein intake, is crucial for optimizing nutritional care and outcomes in patients with cancer. Validation of dietary assessment methods is necessary to ensure accuracy, but the validity of these methods in patients with cancer, and especially in those with cancer cachexia, is uncertain. Validating nutritional intake is complex because of the variety of dietary methods, lack of a gold standard method, and diverse validation measures. Here, we review the literature on validations of dietary intake methods in patients with cancer, including those with cachexia, and highlight the gap between current validation efforts and the need for accurate dietary assessment methods in this population.

Recent findings: We analyzed eight studies involving 1479 patients with cancer to evaluate the accuracy and reliability of 24-hour recalls, food records, and food frequency questionnaires in estimating energy and protein intake. We discuss validation methods, including comparison with biomarkers, indirect calorimetry, and relative validation of dietary intake methods.

Summary: Few have validated dietary intake methods against objective markers in patients with cancer. While food records and 24-hour recalls show potential accuracy for energy and protein intake, this may be compromised in hypermetabolic patients. Additionally, under- and overreporting of intake may be less frequent, and the reliability of urinary nitrogen as a protein intake marker in patients with cachexia needs further investigation. Accurate dietary assessment is important for enhancing nutritional care outcomes in cachexia trials, requiring validation at multiple time points throughout the cancer trajectory.

综述目的:准确评估膳食摄入量,尤其是能量和蛋白质摄入量,对于优化癌症患者的营养护理和治疗效果至关重要。为确保准确性,有必要对膳食评估方法进行验证,但这些方法在癌症患者,尤其是癌症恶病质患者中的有效性尚不确定。由于膳食方法多种多样,缺乏金标准方法,验证措施也多种多样,因此营养摄入量的验证非常复杂。在此,我们回顾了有关癌症患者(包括恶病质患者)膳食摄入方法验证的文献,并强调了当前验证工作与该人群对准确膳食评估方法的需求之间的差距:我们分析了涉及 1479 名癌症患者的 8 项研究,以评估 24 小时回忆、食物记录和食物频率问卷在估算能量和蛋白质摄入量方面的准确性和可靠性。我们讨论了验证方法,包括与生物标记物、间接热量计的比较,以及膳食摄入方法的相对验证:很少有人将膳食摄入量方法与癌症患者的客观指标进行验证。虽然食物记录和 24 小时回忆显示了能量和蛋白质摄入量的潜在准确性,但这可能会影响高代谢患者的摄入量。此外,少报和多报摄入量的情况可能较少发生,尿氮作为恶病质患者蛋白质摄入量标记的可靠性需要进一步研究。准确的膳食评估对提高恶病质试验中的营养护理效果非常重要,需要在癌症病程的多个时间点进行验证。
{"title":"Validity of dietary intake methods in cancer cachexia.","authors":"Trude R Balstad, Marianne Bråtveit, Tora S Solheim, Lisa Heide Koteng, Asta Bye, Rasmus Dahl Jakobsen, Bente Schødt-Osmo, Siv Hilde Fjeldstad, Marianne Erichsen, Ola Magne Vagnildhaug, Ingvild Paur, Inger Ottestad","doi":"10.1097/SPC.0000000000000709","DOIUrl":"10.1097/SPC.0000000000000709","url":null,"abstract":"<p><strong>Purpose of review: </strong>Accurate assessment of dietary intake, especially energy and protein intake, is crucial for optimizing nutritional care and outcomes in patients with cancer. Validation of dietary assessment methods is necessary to ensure accuracy, but the validity of these methods in patients with cancer, and especially in those with cancer cachexia, is uncertain. Validating nutritional intake is complex because of the variety of dietary methods, lack of a gold standard method, and diverse validation measures. Here, we review the literature on validations of dietary intake methods in patients with cancer, including those with cachexia, and highlight the gap between current validation efforts and the need for accurate dietary assessment methods in this population.</p><p><strong>Recent findings: </strong>We analyzed eight studies involving 1479 patients with cancer to evaluate the accuracy and reliability of 24-hour recalls, food records, and food frequency questionnaires in estimating energy and protein intake. We discuss validation methods, including comparison with biomarkers, indirect calorimetry, and relative validation of dietary intake methods.</p><p><strong>Summary: </strong>Few have validated dietary intake methods against objective markers in patients with cancer. While food records and 24-hour recalls show potential accuracy for energy and protein intake, this may be compromised in hypermetabolic patients. Additionally, under- and overreporting of intake may be less frequent, and the reliability of urinary nitrogen as a protein intake marker in patients with cachexia needs further investigation. Accurate dietary assessment is important for enhancing nutritional care outcomes in cachexia trials, requiring validation at multiple time points throughout the cancer trajectory.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital clinics for diagnosing and treating migraine. 诊断和治疗偏头痛的数字诊所。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1097/SPC.0000000000000715
Johan Nyberg, Rikard Rosenbacke, Elinor Ben-Menachem

Purpose of review: Several innovative digital technologies have begun to be applied to diagnosing and treating migraine. We reviewed the potential benefits and opportunities from delivering migraine care through comprehensive digital clinics.

Recent findings: There are increasing applications of digitization to migraine diagnosis and management, including e-diaries, and patient self-management, especially after the COVID-19 pandemic. Digital care delivery appears to better engage chronic migraine sufferers who may struggle to present to physical clinics.

Summary: Digital clinics appear to be a promising treatment modality for patients with chronic migraine. They potentially minimize travel time, shorten waiting periods, improve usability, and increase access to neurologists. Additionally, they have the potential to provide care at a much lower cost than traditional physical clinics. However, the current state of evidence mostly draws on case-reports, suggesting a need for future randomized trials comparing digital interventions with standard care pathways.

回顾的目的:一些创新型数字技术已开始应用于偏头痛的诊断和治疗。我们回顾了通过综合数字诊所提供偏头痛治疗的潜在益处和机遇:数字化在偏头痛诊断和管理中的应用越来越多,包括电子日记和患者自我管理,尤其是在COVID-19大流行之后。数字化医疗服务似乎能更好地吸引那些难以到实体诊所就诊的慢性偏头痛患者。摘要:对于慢性偏头痛患者来说,数字化诊所似乎是一种很有前景的治疗模式。它们有可能最大限度地减少患者的旅行时间,缩短等待时间,提高可用性,并增加患者接触神经科医生的机会。此外,与传统的实体诊所相比,它们有可能以更低的成本提供医疗服务。然而,目前的证据大多来自病例报告,这表明未来需要进行随机试验,将数字干预与标准护理路径进行比较。
{"title":"Digital clinics for diagnosing and treating migraine.","authors":"Johan Nyberg, Rikard Rosenbacke, Elinor Ben-Menachem","doi":"10.1097/SPC.0000000000000715","DOIUrl":"10.1097/SPC.0000000000000715","url":null,"abstract":"<p><strong>Purpose of review: </strong>Several innovative digital technologies have begun to be applied to diagnosing and treating migraine. We reviewed the potential benefits and opportunities from delivering migraine care through comprehensive digital clinics.</p><p><strong>Recent findings: </strong>There are increasing applications of digitization to migraine diagnosis and management, including e-diaries, and patient self-management, especially after the COVID-19 pandemic. Digital care delivery appears to better engage chronic migraine sufferers who may struggle to present to physical clinics.</p><p><strong>Summary: </strong>Digital clinics appear to be a promising treatment modality for patients with chronic migraine. They potentially minimize travel time, shorten waiting periods, improve usability, and increase access to neurologists. Additionally, they have the potential to provide care at a much lower cost than traditional physical clinics. However, the current state of evidence mostly draws on case-reports, suggesting a need for future randomized trials comparing digital interventions with standard care pathways.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanistic insights into behavioral clusters associated with cancer-related systemic inflammatory response. 洞察与癌症相关的全身炎症反应行为集群的机制。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1097/SPC.0000000000000706
Taichi Goto, Leorey N Saligan

Purpose of review: This focused, narrative review mostly describes our team's investigations into the potential inflammatory mechanisms that contribute to the development of cancer-related gastrointestinal (GI) mucositis and its associated symptoms. This review summarizes details of our clinical and preclinical findings to test the role of inflammation in the development and occurrence of these cancer-related conditions.

Recent findings: GI mucositis (GIM) is a common, distressing condition reported by cancer patients. GIM is often clustered with other behaviors including fatigue, pain, anorexia, depression, and diarrhea. It is hypothesized that there is a common biologic mechanism underpinning this symptom cluster. Our multi-platform investigations revealed that GIM and its associated cluster of behaviors may be triggered by local inflammation spreading systemically causing pro-inflammatory-mediated toxicities, leading to alterations in immune, metabolic, and nervous system functions and activities. For example, behavioral toxicities related to local irradiation for non-metastatic cancer may be triggered by mGluR5 activation influencing prolonged T cell as well as NF-κB transcription factor activities. Thus, interventions targeting inflammation and associated pathways may be a reasonable strategy to alleviate GIM and its symptom cluster.

Summary: GIM may be a sign of a broader systemic inflammatory response triggered by cancer or its treatment. Addressing GIM and its associated symptoms primarily involves supportive care strategies focused on relieving symptoms, promoting healing, and preventing complications.

综述的目的:这篇重点突出的叙述性综述主要介绍了我们团队对导致癌症相关胃肠道(GI)粘膜炎及其相关症状发生的潜在炎症机制的研究。本综述总结了我们的临床和临床前研究结果的细节,以检验炎症在这些癌症相关症状的发生和发展中的作用:消化道粘膜炎(GIM)是癌症患者报告的一种常见的、令人痛苦的症状。胃肠道粘膜炎通常与疲劳、疼痛、厌食、抑郁和腹泻等其他行为聚集在一起。据推测,这种症状群有一个共同的生物机制。我们的多平台研究发现,GIM 及其相关的行为集群可能是由局部炎症引发的,炎症扩散到全身,引起炎症介导的毒性反应,导致免疫、代谢和神经系统功能和活动的改变。例如,与局部照射治疗非转移性癌症有关的行为毒性可能是由于 mGluR5 激活影响了 T 细胞和 NF-κB 转录因子活动的延长而引发的。因此,针对炎症和相关途径的干预措施可能是缓解 GIM 及其症状群的合理策略。摘要:GIM 可能是癌症或其治疗引发的更广泛的全身性炎症反应的一种表现。解决 GIM 及其相关症状主要涉及支持性护理策略,重点是缓解症状、促进愈合和预防并发症。
{"title":"Mechanistic insights into behavioral clusters associated with cancer-related systemic inflammatory response.","authors":"Taichi Goto, Leorey N Saligan","doi":"10.1097/SPC.0000000000000706","DOIUrl":"10.1097/SPC.0000000000000706","url":null,"abstract":"<p><strong>Purpose of review: </strong>This focused, narrative review mostly describes our team's investigations into the potential inflammatory mechanisms that contribute to the development of cancer-related gastrointestinal (GI) mucositis and its associated symptoms. This review summarizes details of our clinical and preclinical findings to test the role of inflammation in the development and occurrence of these cancer-related conditions.</p><p><strong>Recent findings: </strong>GI mucositis (GIM) is a common, distressing condition reported by cancer patients. GIM is often clustered with other behaviors including fatigue, pain, anorexia, depression, and diarrhea. It is hypothesized that there is a common biologic mechanism underpinning this symptom cluster. Our multi-platform investigations revealed that GIM and its associated cluster of behaviors may be triggered by local inflammation spreading systemically causing pro-inflammatory-mediated toxicities, leading to alterations in immune, metabolic, and nervous system functions and activities. For example, behavioral toxicities related to local irradiation for non-metastatic cancer may be triggered by mGluR5 activation influencing prolonged T cell as well as NF-κB transcription factor activities. Thus, interventions targeting inflammation and associated pathways may be a reasonable strategy to alleviate GIM and its symptom cluster.</p><p><strong>Summary: </strong>GIM may be a sign of a broader systemic inflammatory response triggered by cancer or its treatment. Addressing GIM and its associated symptoms primarily involves supportive care strategies focused on relieving symptoms, promoting healing, and preventing complications.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mirogabalin: a novel gabapentinoid or another false dawn? 米罗加巴林:新型加巴喷丁类药物还是另一个假曙光?
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/SPC.0000000000000714
Thomas J Craig, Paul Farquhar-Smith

Purpose of review: Mirogabalin is a novel gabapentinoid medication for the treatment of neuropathic pain. The purpose of this review is to discuss current evidence for its use. Gabapentinoids are widely prescribed for neuropathic pain. Mirogabalin offers theoretical advantages over traditional gabapentinoids due to its specificity for the α2δ-1 subunit of voltage-gated calcium channels. It is theorised that this specificity may reduce adverse drug reactions by minimising binding to the α2δ-2 subunit which is responsible for many of the gabapentinoid side effects.

Recent findings: Mirogabalin's slower dissociation from the α2δ-1 compared with α2δ-2, and its higher potency may also impart an efficacy benefit over traditional gabapentinoids. These theoretical advantages of mirogabalin remain inconclusive in clinical practice, with mixed evidence regarding mirogabalin versus traditional gabapentinoids. Some studies suggest a reduced side effect profile yet, others fail to demonstrate significant differences. Regarding efficacy, mirogabalin may be superior to placebo for several neuropathic pain syndromes, but evidence of widespread benefit over traditional gabapentinoids is currently lacking.

Summary: Mirogabalin offers theoretical promise, but large, independent studies are required to further assess its performance versus traditional gabapentinoids.

综述目的:米罗加滨是一种治疗神经性疼痛的新型加巴喷丁类药物。本综述旨在讨论其使用的现有证据。加巴喷丁类药物被广泛用于治疗神经性疼痛。与传统的加巴喷丁类药物相比,米罗加滨具有理论上的优势,因为它对电压门控钙通道的α2δ-1亚基具有特异性。据推测,这种特异性可最大限度地减少与α2δ-2亚基的结合,从而减少药物不良反应,而α2δ-2亚基是造成许多加巴喷丁类药物副作用的原因:最新发现:与α2δ-2亚基相比,米罗加巴林与α2δ-1亚基的解离速度较慢,而且药效更强,这也可能使其在疗效上优于传统的加巴喷丁类药物。米瑞巴林的这些理论优势在临床实践中仍无定论,有关米瑞巴林与传统加巴喷丁类药物的证据不一。一些研究表明米瑞巴林的副作用有所减轻,但另一些研究则未能证明两者之间存在显著差异。在疗效方面,米罗卡巴林对几种神经病理性疼痛综合征的疗效可能优于安慰剂,但目前尚缺乏证据表明米罗卡巴林比传统的加巴喷丁类药物具有更广泛的疗效。小结:米罗卡巴林具有理论上的前景,但还需要进行大规模的独立研究,以进一步评估其与传统加巴喷丁类药物相比的性能。
{"title":"Mirogabalin: a novel gabapentinoid or another false dawn?","authors":"Thomas J Craig, Paul Farquhar-Smith","doi":"10.1097/SPC.0000000000000714","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000714","url":null,"abstract":"<p><strong>Purpose of review: </strong>Mirogabalin is a novel gabapentinoid medication for the treatment of neuropathic pain. The purpose of this review is to discuss current evidence for its use. Gabapentinoids are widely prescribed for neuropathic pain. Mirogabalin offers theoretical advantages over traditional gabapentinoids due to its specificity for the α2δ-1 subunit of voltage-gated calcium channels. It is theorised that this specificity may reduce adverse drug reactions by minimising binding to the α2δ-2 subunit which is responsible for many of the gabapentinoid side effects.</p><p><strong>Recent findings: </strong>Mirogabalin's slower dissociation from the α2δ-1 compared with α2δ-2, and its higher potency may also impart an efficacy benefit over traditional gabapentinoids. These theoretical advantages of mirogabalin remain inconclusive in clinical practice, with mixed evidence regarding mirogabalin versus traditional gabapentinoids. Some studies suggest a reduced side effect profile yet, others fail to demonstrate significant differences. Regarding efficacy, mirogabalin may be superior to placebo for several neuropathic pain syndromes, but evidence of widespread benefit over traditional gabapentinoids is currently lacking.</p><p><strong>Summary: </strong>Mirogabalin offers theoretical promise, but large, independent studies are required to further assess its performance versus traditional gabapentinoids.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In support of rigor and reproducibility in cancer cachexia research. 支持癌症恶病质研究的严谨性和可重复性。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/SPC.0000000000000708
Aminah Jatoi, Barry Laird
{"title":"In support of rigor and reproducibility in cancer cachexia research.","authors":"Aminah Jatoi, Barry Laird","doi":"10.1097/SPC.0000000000000708","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000708","url":null,"abstract":"","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The systemic outcomes of gastrointestinal mucositis: host-microbe interaction leading to systemic inflammatory responses. 胃肠道粘膜炎的全身后果:宿主与微生物相互作用导致全身炎症反应。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2024-06-01 Epub Date: 2024-04-30 DOI: 10.1097/SPC.0000000000000704
Andrea Stringer
{"title":"The systemic outcomes of gastrointestinal mucositis: host-microbe interaction leading to systemic inflammatory responses.","authors":"Andrea Stringer","doi":"10.1097/SPC.0000000000000704","DOIUrl":"10.1097/SPC.0000000000000704","url":null,"abstract":"","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supportive care measures for bispecific T-cell engager therapies in haematological malignancies. 血液恶性肿瘤双特异性 T 细胞捕获疗法的支持性护理措施。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2024-04-23 DOI: 10.1097/SPC.0000000000000699
Lucia Y Chen, J. Kothari
PURPOSE OF REVIEWBispecific T-cell engager (TCE) therapies are revolutionizing the treatment of several haematological malignancies, including B-cell acute lymphoblastic leukaemia, various subtypes of B-cell non-Hodgkin lymphoma, and multiple myeloma. Due to their unique mode of action in activating endogenous T cells, they are associated with several important early side effects, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as target-specific toxicities and a significant risk of infection.RECENT FINDINGSCurrently, supportive care measures for TCEs have largely been inferred from other T-cell therapies, such as CAR-T (chimeric antigen receptor) therapy. Further research into TCE-specific supportive care measures is needed to improve the tolerability of these therapies for patients. A key question moving forward is understanding how to predict and minimize early toxicity (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). Associated infection risk is a significant cause of patient morbidity, therefore a better understanding of how to optimize TCE-dosing and prophylactic measures, such as intravenous immunoglobulin and antimicrobials, will be crucial to achieving an improved balance of toxicity and efficacy. Enabling early outpatient delivery of these therapies to select patients at lower risk of toxicity may also help to improve patient experience and quality of life.SUMMARYHere we review up-to-date guidance and literature on existing supportive care measures for bispecific TCE therapy-related toxicities. We highlight both unique and serious side effects of TCE therapies that require improved management strategies to enable more patients to benefit from these efficacious drugs.
综述目的 双特异性 T 细胞吞噬(TCE)疗法正在彻底改变多种血液恶性肿瘤的治疗方法,包括 B 细胞急性淋巴细胞白血病、各种亚型的 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。由于其激活内源性T细胞的独特作用模式,它们与几种重要的早期副作用有关,包括细胞因子释放综合征和免疫效应细胞相关神经毒性综合征,以及靶点特异性毒性和显著的感染风险。目前,针对TCE的支持性护理措施主要是从其他T细胞疗法(如CAR-T(嵌合抗原受体)疗法)中推断出来的。需要进一步研究针对 TCE 的支持性护理措施,以提高患者对这些疗法的耐受性。今后的一个关键问题是了解如何预测和尽量减少早期毒性(细胞因子释放综合征和免疫效应细胞相关神经毒性综合征)。相关的感染风险是导致患者发病的一个重要原因,因此,更好地了解如何优化 TCE 剂量和预防措施(如静脉注射免疫球蛋白和抗菌药物),对于改善毒性和疗效之间的平衡至关重要。在此,我们回顾了针对双特异性 TCE 治疗相关毒性的现有支持性护理措施的最新指南和文献。我们强调了双特异性 TCE 疗法的独特副作用和严重副作用,这些副作用需要改进管理策略,以使更多患者从这些高效药物中获益。
{"title":"Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.","authors":"Lucia Y Chen, J. Kothari","doi":"10.1097/SPC.0000000000000699","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000699","url":null,"abstract":"PURPOSE OF REVIEW\u0000Bispecific T-cell engager (TCE) therapies are revolutionizing the treatment of several haematological malignancies, including B-cell acute lymphoblastic leukaemia, various subtypes of B-cell non-Hodgkin lymphoma, and multiple myeloma. Due to their unique mode of action in activating endogenous T cells, they are associated with several important early side effects, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as target-specific toxicities and a significant risk of infection.\u0000\u0000\u0000RECENT FINDINGS\u0000Currently, supportive care measures for TCEs have largely been inferred from other T-cell therapies, such as CAR-T (chimeric antigen receptor) therapy. Further research into TCE-specific supportive care measures is needed to improve the tolerability of these therapies for patients. A key question moving forward is understanding how to predict and minimize early toxicity (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). Associated infection risk is a significant cause of patient morbidity, therefore a better understanding of how to optimize TCE-dosing and prophylactic measures, such as intravenous immunoglobulin and antimicrobials, will be crucial to achieving an improved balance of toxicity and efficacy. Enabling early outpatient delivery of these therapies to select patients at lower risk of toxicity may also help to improve patient experience and quality of life.\u0000\u0000\u0000SUMMARY\u0000Here we review up-to-date guidance and literature on existing supportive care measures for bispecific TCE therapy-related toxicities. We highlight both unique and serious side effects of TCE therapies that require improved management strategies to enable more patients to benefit from these efficacious drugs.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140666346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Supportive and Palliative Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1